These HIF2α antagonists show inhibitory effects in vivo than those of the tyrosine kinase inhibitor sunitinib, which is used as a standard first-line therapy for metastatic ccRCC. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.